Taken together, these immunophenotyping results show that local αCD45-Cyt therapy is not only able to dramatically alter the treated tumor immune microenvironment (TME), as other local therapies have accomplished, but also to reprogram the tumor-specific CD8+ population in the TDLNs, correlating with stronger abscopal responses. Here, CD8A is linked to neoplasm.